Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Provention Bio

Lisa Jarvis: A diabetes breakthrough in search of patients

In a first, the U.S. Food and Drug Administration has approved a therapy that slows the onset of Type 1 diabetes. Teplizumab, developed by Provention Bio, typically delays the need for insulin shots, blood-sugar monitoring, and diet control by about two years. For some, the effect lasted years longer.

Tribune News Service

Why Aehr Test Systems Shares Are Trading Higher By Over 19%, Here Are 51 Stocks Moving In Friday's Mid-Day Session

Why Aehr Test Systems Shares Are Trading Higher By Over 19%, Here Are 51 Stocks Moving In Friday's Mid-Day Session

Gainers Innovative Eyewear, Inc. (NASDAQ: LUCY) jumped 108% to $3.3943 on abnormally-high volume. The company released its October investor presentation yesterday.

Dow Drops Over 400 Points After US Economy Adds 263,000 Jobs During September

Dow Drops Over 400 Points After US Economy Adds 263,000 Jobs During September

U.S. stocks traded lower this morning, with the Dow Jones dropping more than 400 points on Friday.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

12 Health Care Stocks Moving In Thursday's Intraday Session

Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2022

The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact

Here's a roundup of top developments in the biotech space over the last 24 hours:

U.S. FDA Extends Review By Three Months For Provention Bio's Type 1 Diabetes Candidate

The U.S. Food and Drug Administration (FDA) has extended its review period by three months for Provention Bio’s (NASDAQ: PRVB) Biologics License Application (BLA) for teplizumab in patients with type 1 diabetes. The regulatory agency has set a new target action goal date of November 17, 2022.

inkl

Read news from The Economist, FT, and more,
with one subscription

Provention Bio Earnings Conference Call Is Coming Up, Here's What You Need To Know

Provention Bio Earnings Conference Call Is Coming Up, Here's What You Need To Know

Provention Bio (NASDAQ:PRVB) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. How to Attend Provention Bio (PRVB) Conference Call Follow this link to access the live webcast.

The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron

The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron

Here's a roundup of top developments in the biotech space over the last 24 hours:

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Western Digital

B of A Securities

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

323,088 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play